The phase 3 clinical program for Merck's (NYSE: MRKIn response to the preladenant trial results, Dr. David Michelson, vice president of clinical research,
neuroscience, and ophthalmology at Merck research laboratories, said, "Parkinson's disease is very ...
[Published Motley Fool - 21 hours ago]